Retrospective Analysis of the Real-World Use of Topical Antimicrobials in the Paediatric Population with Impetigo in Italy: Focus on the Role of Ozenoxacin 1% Cream
Elisa Barbieri,
Sara Cavagnis,
Riccardo Boracchini,
Antonio Scamarcia,
Angela Testa,
Maria Grazia Ciarniello,
Biancangela Martinelli,
Luigi Cantarutti,
Carlo Giaquinto,
Anna Cantarutti
Affiliations
Elisa Barbieri
Division of Pediatric Infectious Diseases, Department for Woman and Child Health, University of Padua, 35128 Padua, Italy
Sara Cavagnis
Società Servizi Telematici—Pedianet, 35100 Padua, Italy
Riccardo Boracchini
Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy
Antonio Scamarcia
Società Servizi Telematici—Pedianet, 35100 Padua, Italy
Angela Testa
Angelini Pharma S.p.A., 00181 Rome, Italy
Maria Grazia Ciarniello
Angelini Pharma S.p.A., 00181 Rome, Italy
Biancangela Martinelli
Angelini Pharma S.p.A., 00181 Rome, Italy
Luigi Cantarutti
Società Servizi Telematici—Pedianet, 35100 Padua, Italy
Carlo Giaquinto
Division of Pediatric Infectious Diseases, Department for Woman and Child Health, University of Padua, 35128 Padua, Italy
Anna Cantarutti
Unit of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy
Using electronic data from a large population-based network of Family Paediatricians (Pedianet), we aimed to describe the use of topical antimicrobials, including ozenoxacin 1% cream, in impetigo in children in Italy. We included 2929 children aged 6 months–14 years from 2016 to 2019 with at least one episode of impetigo treated with topical antimicrobials. Overall, 3051 cases of impetigo were included in the analysis. Treatment started in most cases on the same day as the impetigo diagnosis and lasted around eight days. In about 8% of the cases, a systemic antibiotic was prescribed after the topical antimicrobial, usually after 4–14 days. In this study, ozenoxacin was used in 8% of the cases. Treatment duration was significantly shorter for patients prescribed ozenoxacin compared to the whole study population (median of six vs. seven days, respectively). In contrast, the rate of treatment failure was similar. Very few adverse reactions were identified.
